Gilead Sciences To Release Third Quarter 2012 Financial Results On Tuesday, October 23, 2012

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2012 financial results will be released on Tuesday, October 23, at 4:05 p.m. Eastern Time. At 4:15 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the third quarter 2012 and provide a general business update. The conference call will be accessible via the internet from the company’s website.

To access the webcast link, log on to www.gilead.com. Please connect to the company’s website at least 15 minutes prior to the conference call to ensure adequate time for any software download that may be required to listen to the webcast. Alternatively, please call 1-800-659-1966 (U.S.) or 1-617-614-2711 (international) and dial the participant passcode 31853534 to access the call. Telephone replay will be available approximately two hours after the call through 11:59 p.m. Eastern Time, October 26, 2012. To access the replay, please call 1-888-286-8010 (U.S.) or 1-617-801-6888 (international) and dial the participant passcode 84574172. The webcast will be archived on www.gilead.com for one year.

About Gilead

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.

For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

Copyright Business Wire 2010

If you liked this article you might like

Don't Get Shaken Out of Good Stocks: Cramer's 'Mad Money' Recap (Wed 9/13/17)

Juno, bluebird In Focus as Targets Following Gilead-Kite Aquisition

Faster Rebuild After Harvey; Micron Tech Breakout Would Be a Win: Best of Cramer